SELLAS Life Sciences Group, Inc. — Director's Dealing 2014

Apr 10, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2014-01-23

Reporting Person: KRIEGSMAN STEVEN A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-01-23	Common Stock	M	100000	$1.18	Acquired	105000	Direct
2014-01-23	Common Stock	M	50000	$2.31	Acquired	155000	Direct
2014-01-23	Common Stock	S	150000	$5.9236	Disposed	5000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-01-23	Stock Option (right to buy)	$1.18	M	100000	Disposed	2021-03-24	Common Stock (100000)	Direct
2014-01-23	Stock Option (right to buy)	$2.31	M	50000	Disposed	2021-01-13	Common Stock (50000)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.8845 to $5.9722 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: The option vested in equal quarterly installments of 25,000 shares on each of June 25, 2011, September 25, 2011, December 25, 2011 and March 25, 2012.

F3: The option vested in equal quarterly installments of 12,500 shares on each of March 31, 2011, June 30, 2011, September 30, 2011 and December 31, 2011.